Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/11/2019
SIETES contiene 92833 citas

 
 
<< anterior 41 a 60 de 114 siguiente >>
Presentar resultados
Seleccionar todas
41.Enlace a cita original Cita con resumen
Anónimo. Atypical antipsychotics and agranulocytosis. Canadian Adverse Reaction Newsleter 2009;19:1-2. [Ref.ID 85691]
42.Tiene citas relacionadas Cita con resumen
Shah S. Pfizer ends 2008 on a disappointing note. Scrip 2009;3430:7. [Ref.ID 85169]
43.Tiene citas relacionadas Cita con resumen
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41. [Ref.ID 84954]
44.Tiene citas relacionadas Cita con resumen
Kahn RS, Fleischhacker WW, Boter H, Davidson M. Are all antipsychotics equal? Authors' reply. Lancet 2008;372:202. [Ref.ID 83622]
45.Tiene citas relacionadas Cita con resumen
Volavka J. Are all antipsychotics equal?. Lancet 2008;372:201-2. [Ref.ID 83621]
46.
Said Q, Gutterman EM, Kim MS, Firth SD, Whitehead R, Brixner D. Somnolence effiects of antipsychotic medications and the risk of unintentional injury. Pharmacoepidemiol Drug Saf 2008;17:354-64. [Ref.ID 82713]
47.Tiene citas relacionadas Cita con resumen
Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE, for the EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-97. [Ref.ID 82495]
48.Tiene citas relacionadas
Rosenheck RA. Pharmacotherapy of first-episode schizophrenia. Lancet 2008;371:1048-9. [Ref.ID 82488]
49. Cita con resumen
Anónimo. Pfizer lifts outlook as Lyrica and Chantix prop up sales in 2007. Scrip 2008;3331:9. [Ref.ID 82104]
50.Tiene citas relacionadas Cita con resumen
Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA, for the CATIE Investigators and the Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007;64:633-50. [Ref.ID 80179]
52.Tiene citas relacionadas Cita con resumen
Roth BL. Dopamine agonists and valvular heart disease. Dr. Roth replies. N Engl J Med 2007;356:1679-80. [Ref.ID 79842]
53.Tiene citas relacionadas Cita con resumen
Schade R, Andersohn F, Garbe E. Dopamine agonists and valvular heart disease. Dr. Schade and colleagues reply. N Engl J Med 2007;356:1678. [Ref.ID 79840]
54.Tiene citas relacionadas Cita con resumen
Kast RE, Altschuler EL. Dopamine agonists and valvular heart disease. N Engl J Med 2007;356:1677. [Ref.ID 79837]
55. Cita con resumen
Anónimo. "Evidence lacking" to support off-label use with atypical antipsychotics. Scrip 2007;3229:23. [Ref.ID 79059]
57.
Besag FMC, Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Saf 2006;29:95-118. [Ref.ID 77461]
58.
Ganguli R, Strassnig M. Are older antipsychotic drugs obsolete?. BMJ 2006;332:1346-7. [Ref.ID 77215]
59.
Isbister GK, Balit CR, Kilham HA. Antipsychotic poisoning in young children: a systematic review. Drug Saf 2005;28:1029-44. [Ref.ID 75376]
60.
Danielyan A, Kowatch RA. Management options for bipolar disorder in children and adolescents. Pediatr Drugs 2005;7:277-94. [Ref.ID 75277]
Seleccionar todas
 
<< anterior 41 a 60 de 114 siguiente >>